TargetRNA

TargetRNA is a private, pre-clinical stage biotech pioneering a novel approach to drug discovery by targeting RNA directly with small molecules. Its core technology platform integrates nuclear magnetic resonance (NMR) spectroscopy with computational modeling and molecular dynamics simulations to overcome historical challenges in drugging RNA. The company aims to translate its platform into a pipeline of novel therapeutics for diseases driven by dysregulated RNA, positioning itself at the forefront of the expanding RNA-targeted drug discovery field. As a platform company, it is currently pre-revenue and focused on advancing its technology and initial programs.

Integrated platform using NMR spectroscopy to obtain experimental ligand-binding data, which guides molecular dynamics simulations to build accurate structural models of RNA-ligand complexes for rational drug optimization.

TargetRNA competes in the emerging field of RNA-targeted small molecule drug discovery against companies like Arrakis Therapeutics, Skyhawk Therapeutics, Remix Therapeutics, and Expansion Therapeutics. Large pharma companies are also active in this space through internal efforts and partnerships. Competition is focused on technological approach, intellectual property, and speed to clinical validation.